Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma | Zendy

Qiyun Ou | Zendy; Yunfang Yu | Zendy; Anlin Li | Zendy; Jie Chen | Zendy; Tingting Yu | Zendy; Xiaolin Xu | Zendy; Xinxin Xie | Zendy; Yongjian Chen | Zendy; Dagui Lin | Zendy; Qiaohong Zeng | Zendy; Yuxin Zhang | Zendy; Xudong Tang | Zendy; Herui Yao | Zendy; Baoming Luo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma

Author(s) -

Qiyun Ou,

Yunfang Yu,

Anlin Li,

Jie Chen,

Tingting Yu,

Xiaolin Xu,

Xinxin Xie,

Yongjian Chen,

Dagui Lin,

Qiaohong Zeng,

Yuxin Zhang,

Xudong Tang,

Herui Yao,

Baoming Luo

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.01.32

Subject(s) - hepatocellular carcinoma , immunotherapy , medicine , signature (topology) , mutation , carcinoma , oncology , cancer research , biology , cancer , gene , genetics , geometry , mathematics

Immunotherapy showed longer OS and PFS than conventional therapy among HCC patients, especially patients with a low mutation risk score. The nomogram based on genomic and clinical characteristics is effective in predicting survival of HCC patients undergoing immune checkpoint inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research